COLUMBIA, Md., March 18 /PRNewswire-FirstCall/ -- Celsion Corporation today announced that an abstract about the Phase I/II trial of ThermoDox(R) in Recurrent Chest Wall Cancer (RCW) has been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting. The abstract presents the background, rationale, and design of the DIGNITY study which is ongoing and evaluating ThermoDox in combination with hyperthermia in women with recurrent breast cancer on their chest wall. The ASCO Annual Meeting will be held June 4 - 8, 2010 at the McCormick Place Convention Center in Chicago, Illinois.
"We are pleased that our study was among those that were accepted providing continued evidence of the medical community's high interest level in ThermoDox, the progress of our clinical program, and our focus on a cancer that is very difficult to treat," commented Michael H. Tardugno, Celsion's President and Chief Executive Officer. "We are grateful for the commitment of our clinical investigators to this important work and look forward to their on-going participation in the DIGNITY trial."
About the DIGNITY Clinical Trial
The DIGNITY clinical trial is a Phase I/II open label, dose escalating trial to evaluate the safety and efficacy of ThermoDox(R) with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer, an aggressive form of cancer with a poor prognosis and limited treatment options. The primary endpoint in the DIGNITY trial is durable complete local response at the tumor site. Once the safe dose is determined Celsion intends to enroll up to 100 patients to establish efficacy. The results from the DIGNITY trial are expected to build on the promising data from the Phase I dose escalation study currently being conducted at Duke University Medical Center.
ThermoDox(R) has also demonstrated evidence of efficacy in a Phase I study for primary liver cancer. Celsion has been granted FDA Orphan Drug designation for ThermoDox(R) and is conducting a pivotal 600 patient global Phase III study in primary liver cancer under a FDA Special Protocol Assessment.
ThermoDox(R) is a registered trademark of Celsion Corporation.
For more information on Celsion, visit our website: http://www.celsion.com.
CONTACT: Tricia Swanson, The Trout Group, +1-617-583-1306,
tswanson@troutgroup.com, for Celsion Corporation
Web site: http://www.celsion.com/
